Literature DB >> 28031415

Evaluation of Batch Variations in Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes from 2 Major Suppliers.

Jianhua Huo1,2, Archana Kamalakar1, Xi Yang3, Beverly Word1, Norman Stockbridge4, Beverly Lyn-Cook1, Li Pang1.   

Abstract

Drug-induced proarrhythmia is a major safety issue in drug development. Developing sensitive in vitro assays that can predict drug-induced cardiotoxicity in humans has been a challenge of toxicology research for decades. Recently, induced pluripotent stem cell-derived human cardiomyocytes (iPSC-hCMs) have become a promising model because they largely replicate the electrophysiological behavior of human ventricular cardiomyocytes. Patient-specific iPSC-hCMs have been proposed for personalized cardiac drug selection and adverse drug response prediction; however, many procedures are involved in cardiomyocytes differentiation and purification process, which may result in large line-to-line and batch-to-batch variations. Here, we examined the purity, cardiac ion channel gene expression profile, and electrophysiological response of 3 batches of iPSC-hCMs from each of 2 major cell suppliers. We found that iPSC-hCMs from both vendors had similar purities. Most of the cardiac ion channel genes were expressed uniformly among different batches of iCells, while larger variations were found in Cor.4U cells, particularly in the expression of CACNA1C, KCND2, and KCNA5 genes, which could underlie the differences in baseline beating rate (BR) and field potential duration (FPD) measurements. Although, in general, the electrophysiological responses of different batches of cells to Na+, Ca2+, Ikr, and Iks channel blockers were similar, with Ikr blocker-induced proarrhythmia, the sensitivities were depended on baseline BR and FPD values: cells that beat slower had longer FPD and greater sensitivity to drug-induced proarrhythmia. Careful evaluation of the performance of iPSC-hCMs and methods of data analysis is warranted for shaping regulatory standards in qualifying iPSC-hCMs for drug safety testing. Published by Oxford University Press on behalf of the Society of Toxicology 2016. This work is written by US Government employees and is in the public domain in the US.

Entities:  

Keywords:  drug-induced proarrhythmia; iPSC-CMs; batch variations.

Mesh:

Substances:

Year:  2017        PMID: 28031415     DOI: 10.1093/toxsci/kfw235

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  18 in total

Review 1.  Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms.

Authors:  Li Pang; Philip Sager; Xi Yang; Hong Shi; Frederick Sannajust; Mathew Brock; Joseph C Wu; Najah Abi-Gerges; Beverly Lyn-Cook; Brian R Berridge; Norman Stockbridge
Journal:  Circ Res       Date:  2019-10-10       Impact factor: 17.367

2.  Comparative effects of parent and heated cinnamaldehyde on the function of human iPSC-derived cardiac myocytes.

Authors:  Matthew A Nystoriak; Peter J Kilfoil; Pawel K Lorkiewicz; Bhargav Ramesh; Philip J Kuehl; Jacob McDonald; Aruni Bhatnagar; Daniel J Conklin
Journal:  Toxicol In Vitro       Date:  2019-09-10       Impact factor: 3.500

3.  Validating the Arrhythmogenic Potential of High-, Intermediate-, and Low-Risk Drugs in a Human-Induced Pluripotent Stem Cell-Derived Cardiac Microphysiological System.

Authors:  Verena Charwat; Bérénice Charrez; Brian A Siemons; Henrik Finsberg; Karoline H Jæger; Andrew G Edwards; Nathaniel Huebsch; Samuel Wall; Evan Miller; Aslak Tveito; Kevin E Healy
Journal:  ACS Pharmacol Transl Sci       Date:  2022-07-29

4.  A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential.

Authors:  Jessica A Palmer; Alan M Smith; Vitalina Gryshkova; Elizabeth L R Donley; Jean-Pierre Valentin; Robert E Burrier
Journal:  Toxicol Sci       Date:  2020-04-01       Impact factor: 4.849

5.  Antisense regulation of atrial natriuretic peptide expression.

Authors:  Selvi Celik; Mardjaneh Karbalaei Sadegh; Michael Morley; Carolina Roselli; Patrick T Ellinor; Thomas Cappola; J Gustav Smith; Olof Gidlöf
Journal:  JCI Insight       Date:  2019-10-03

6.  High-content phenotypic assay for proliferation of human iPSC-derived cardiomyocytes identifies L-type calcium channels as targets.

Authors:  Laura A Woo; Svyatoslav Tkachenko; Mei Ding; Alleyn T Plowright; Ola Engkvist; Henrik Andersson; Lauren Drowley; Ian Barrett; Mike Firth; Peter Akerblad; Matthew J Wolf; Stefan Bekiranov; David L Brautigan; Qing-Dong Wang; Jeffrey J Saucerman
Journal:  J Mol Cell Cardiol       Date:  2018-12-28       Impact factor: 5.000

7.  Conventional rigid 2D substrates cause complex contractile signals in monolayers of human induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Eline Huethorst; Peter Mortensen; Radostin D Simitev; Hao Gao; Lotta Pohjolainen; Virpi Talman; Heikki Ruskoaho; Francis L Burton; Nikolaj Gadegaard; Godfrey L Smith
Journal:  J Physiol       Date:  2021-12-07       Impact factor: 6.228

8.  Blinded Contractility Analysis in hiPSC-Cardiomyocytes in Engineered Heart Tissue Format: Comparison With Human Atrial Trabeculae.

Authors:  Ingra Mannhardt; Alexandra Eder; Berengere Dumotier; Maksymilian Prondzynski; Elisabeth Krämer; Martin Traebert; Klaus-Dieter Söhren; Frederik Flenner; Konstantina Stathopoulou; Marc D Lemoine; Lucie Carrier; Torsten Christ; Thomas Eschenhagen; Arne Hansen
Journal:  Toxicol Sci       Date:  2017-07-01       Impact factor: 4.849

Review 9.  Human-Induced Pluripotent Stem Cell Technology and Cardiomyocyte Generation: Progress and Clinical Applications.

Authors:  Angela Di Baldassarre; Elisa Cimetta; Sveva Bollini; Giulia Gaggi; Barbara Ghinassi
Journal:  Cells       Date:  2018-05-25       Impact factor: 6.600

10.  Frequency-dependent drug screening using optogenetic stimulation of human iPSC-derived cardiomyocytes.

Authors:  Hendrik Lapp; Tobias Bruegmann; Daniela Malan; Stephanie Friedrichs; Carsten Kilgus; Alexandra Heidsieck; Philipp Sasse
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.